I read a post about sangamo partnering with Pfizer yesterday on one of their indications. SGMO was at a SP of $24 in March of 2014 and had been beaten down to about $4 recently (sound familiar?). This type of news reminds me that there is a significant thirst for new drugs by BP and deals are happening constantly. I have read that for many BPs the preferred route is to let small biotechs conduct the R&D and then partner or acquire them. I think of P and the 505 2(b) path with potential for a smaller/faster Phase III and what the results could look like. I have to believe that if a BP has signed a CDA on P that they are sitting, watching and ready to pounce when the results are known.